NCT06893354 is a Phase 4 clinical trial of lorlatinib in NSCLC, sponsored by The First Affiliated Hospital of Guangzhou Medical University.

Who is sponsoring NCT06893354?

NCT06893354 is sponsored by The First Affiliated Hospital of Guangzhou Medical University.

What drugs are being tested in NCT06893354?

Interventions in NCT06893354: lorlatinib, lorlatinib plus chemotherapy.

Is NCT06893354 still recruiting?

NCT06893354 is currently not yet recruiting. Last updated 25 March 2025.

Last reviewed 2025-03-25 · How we verify

NCT06893354

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics

Not yet recruiting Phase 4 Last updated 25 March 2025

What this trial tests

Phase 4 trial testing lorlatinib in NSCLC in 20 participants. Not yet recruiting.

Timeline

10 May 2025

Primary endpoint
20 July 2027

20 July 2027

Quick facts

Lead sponsor	The First Affiliated Hospital of Guangzhou Medical University
Phase	Phase 4
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	10 May 2025
Primary completion	20 July 2027
Estimated completion	20 July 2027

Drugs / interventions tested

lorlatinib (lorlatinib) — full drug profile →
lorlatinib plus chemotherapy — full drug profile →

Conditions studied

NSCLC — all drugs for NSCLC →

Sponsor

The First Affiliated Hospital of Guangzhou Medical University

Who can join

18 and older, any sex, with NSCLC. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, randomized, single-center study. This translational study aims to explore tumor microenvironment remodelling after induction therapy lorlatinib and identify mechanisms of disease persistence and potential primary resistance mechanisms of lorlatinib as induction therapy treatment in surgically resectable ALK-rearranged NSCLC by single-cell RNA sequencing (scRNA-seq) and Spatial transcriptomics.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Spatial Transcriptomics in Lung Cancer and Pulmonary Diseases: A Comprehensive Review.
Kang DH, Kim Y, Lee JH, Kang HS, et al · · 2025 · cited 7× · PMID 40563563 · DOI 10.3390/cancers17121912
A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer.
Khan SR, Kotrri E, Breadner D, Kundapur V, et al · · 2025 · PMID 41590340 · DOI 10.3390/curroncol33010020

Verify or expand the search:

Other trials of lorlatinib

Trials testing the same drug.

NCT05834348 — A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in N · completed
NCT05097599 — StrataPATH™ (Precision Indications for Approved Therapies) · Phase 2 · terminated
NCT04753658 — Real World Data Collection Pediatric Neuroblastoma Treated With Lorlatinib · terminated
NCT04800822 — PF-07284892 in Participants With Advanced Solid Tumors · Phase 1 · terminated
NCT04647110 — Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Ther · completed

Other recruiting trials for NSCLC

Currently open trials in the same condition.

NCT07479277 — Progel Platinum for Air Leak Reduction After VATS Lobectomy for NSCLC · NA · recruiting
NCT07323732 — A Study of BIO 300 and Thoracic Radiation Therapy in People With Non-Small Cell Lung Cancer and Interstitial Lung Diseas · Phase 2 · recruiting
NCT07274813 — A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX37 in Advanced/Metastatic Solid Tumors · EARLY_PHASE1 · recruiting
NCT07325864 — Molecular Phenotyping of Primitive Lung Cancer and Metastatic Site · recruiting
NCT07169552 — HC010 in First-line PD-L1 Positive Advanced NSCLC Patients · Phase 2 · recruiting

Other The First Affiliated Hospital of Guangzhou Medical University trials

Trials by the same sponsor.

NCT07413952 — Limertinib Plus Radiotherapy for EGFR-Mutant NSCLC With Brain Metastases · Phase 2 · not yet recruiting
NCT07395375 — Non-intubated Versus Intubated Anesthesia for Thoracoscopic Sublobar Resection · NA · not yet recruiting
NCT07395362 — Hybrid Robot-Assisted Percutaneous Ablation and Non-Intubated VATS for Multiple Pulmonary Nodules · NA · not yet recruiting
NCT07395349 — Safety And Recovery Of Tubeless Strategy In Uniportal VATS Wedge Resection · NA · not yet recruiting
NCT07377916 — Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06893354 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Guangzhou Medical University
Last refreshed: 25 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06893354.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing